David Stein
Internal Medicine · Bronx, NYNPI 1326126640
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $42,280 of the $70,038 with a category attached, or 60.4%. Viiv Healthcare Company accounts for 79.1% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2019 at $52,531 and has fallen 98.3% since, to $902 in 2025. Among internal medicine clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 155 payments — averaging $451.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$55K
- Janssen Products, LP$10K
- Merck$2K
- GSK$1K
- Madrigal Pharmaceuticals$946
- Regeneron Healthcare Solutions, Inc.$194
- plus $310 from 8 others
Across 334 payments — averaging $7051.56 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$2.1M
- Gilead$157K
- Viiv Healthcare Company$54K
- GSK$19K
- AbbVie$13K
- Merck$5K
What the payments were for
- Consulting fees$16,84024%
- Speaking & faculty fees$42,28060%
- Travel & lodging$6,5539%
- Food & beverage$4,3576%
- Education$80%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 65 | $55,430 |
| Janssen Products, LP | 21 | $10,283 |
| Merck | 13 | $1,815 |
| GSK | 9 | $1,059 |
| Madrigal Pharmaceuticals | 33 | $946 |
| Regeneron Healthcare Solutions, Inc. | 3 | $194 |
| Gilead | 2 | $147 |
| QOL Medical, LLC | 1 | $45 |
| Bristol Myers Squibb | 3 | $41 |
| Aimmune Therapeutics, Inc. | 1 | $21 |
| AbbVie | 1 | $15 |
| Livanova USA, Inc. | 1 | $15 |
| Johnson & Johnson | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$70,038 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 121 | $514,501 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 101 | $385,914 |
| DescovyEmtricitabine/Tenofov Alafenam | 146 | $328,188 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 51 | $266,984 |
| TivicayDolutegravir Sodium | 93 | $237,669 |
| JulucaDolutegravir/Rilpivirine | 44 | $164,075 |
| RukobiaFostemsavir Tromethamine | 15 | $128,444 |
| IsentressRaltegravir Potassium | 66 | $121,949 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 29 | $105,654 |
| DovatoDolutegravir Sodium/Lamivudine | 29 | $80,259 |
| PrezcobixDarunavir/Cobicistat | 23 | $77,649 |
| SelzentryMaraviroc | 29 | $55,777 |
| PifeltroDoravirine | 28 | $46,441 |
| TrulicityDulaglutide | 36 | $45,729 |
| EdurantRilpivirine Hcl | 13 | $17,371 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadGenvoya, Biktarvy, Descovy | $147 | $1,228,603368 claims |
| Viiv Healthcare CompanyTivicay, Juluca, Rukobia, Triumeq, Dovato | $55,430 | $716,100210 claims |
| Janssen Products, LPSymtuza | $10,283 | $266,98451 claims |
| MerckIsentress, Pifeltro, Januvia, Janumet | $1,815 | $188,787132 claims |
| Johnson & JohnsonPrezcobix | $14 | $77,64923 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Bronx
- Jason LeiderBronx$694K
- Bulent AtacBronx$647K
- Timothy KanterBronx$630K
- Shervin MortazaviBronx$374K
- Elizabeth Jenny-AvitalBronx$185K
- Meyer HalberstamBronx$143K
- David DoveEast Hampton$12.3M
- Bruce BergerBrooklyn$3.4M
- Nicholas RobinsonBuffalo$2.9M
- Stephen SaletanNew York$2.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.